Multiple Sclerosis Severity Genetics: Why Genotype Alone Cannot Yet Predict Disease Course
Multiple sclerosis (MS) genetics has historically focused on disease susceptibility: why some individuals develop MS while others do not. More than 200 genetic loci have been associated with MS risk, many of them linked to immune regulation. However, predicting disease course—who will accumulate disability rapidly, who will remain relatively stable, and who may transition to progressive disease—remains a major clinical challenge. The article by Kreft and colleagues addresses this gap by testing whether recently reported MS severity-associated genetic variants can predict clinically meaningful outcomes in a real-world cohort of people with MS.
Study Aim: Testing the Clinical Relevance of Severity Genotypes
The central question of the study is not merely whether MS severity variants exist, but whether they are useful for patient-level prognostication. The authors focus particularly on rs10191329A, a single-nucleotide variant previously reported by the International Multiple Sclerosis Genetics Consortium as genome-wide significant for faster disability progression. Because such a finding could potentially influence treatment escalation, counseling, and monitoring intensity, the authors designed their analysis to determine whether this genotype predicts outcomes that neurologists actually use in clinical practice.
Cohort and Methodological Strengths
The study used the South Wales MS registry, a prospective cohort with longitudinal clinical data collected since 1985. After applying inclusion and exclusion criteria, 1,455 people with MS were analyzed. The cohort was especially valuable because it included standardized Expanded Disability Status Scale measurements, disease-modifying treatment exposure, relapse history, anatomical localization of symptoms, and long-term follow-up. Genotyping was performed using established array-based methods followed by imputation and quality control, allowing the investigators to evaluate both the major severity variant rs10191329A and additional suggestive variants reported by earlier GWAS studies.
Main Finding: rs10191329A Did Not Predict Disability Course
Contrary to expectations from the original severity GWAS, rs10191329A was not associated with long-term disability outcomes in this independent cohort. The authors found no meaningful association with age-related MS severity score, time to EDSS 4, EDSS 6, EDSS 8, or conversion to secondary progressive MS. These negative findings were consistent across multiple analytical strategies, including regression models, Kaplan–Meier survival analysis, Cox proportional hazards models, and a propensity score-matched comparison of homozygous risk carriers versus homozygous non-risk carriers.
Broader Phenotyping: No Signal in Relapses or Anatomical Patterns
The authors went beyond global disability scores and examined whether rs10191329A might influence specific clinical features of MS. In people with relapse-onset disease, the variant was not associated with annualized relapse rate, time to second relapse, recovery after the first demyelinating event, anatomical localization at onset, or distribution of relapse localizations over time. This is important because disability accumulation in MS can arise through several mechanisms, including relapse-associated worsening and progression independent of relapse activity. The study found no convincing evidence that rs10191329A influences either pathway in a clinically detectable way.
Secondary Genetic Findings: Modest Replication of Other Variants
Although rs10191329A did not replicate, the study did provide partial support for other candidate severity variants. Two suggestive variants from the MSBase GWAS, rs7289446G and rs868824C, showed associations with long-term disability measures, although their effect sizes were modest. The authors also examined MS susceptibility polygenic risk scores and HLA-related genetic burden, finding that susceptibility genetics did not predict severity. HLA-DRB1*1501 was associated with younger age at onset, but not with long-term disability outcomes, reinforcing the distinction between genetic architecture for MS risk and genetic architecture for MS progression.
Interpretation: Valuable Biology, Limited Current Clinical Utility
The key message of this article is that MS severity genetics is scientifically important but not yet clinically actionable. Variants such as rs10191329A may still provide insight into biological mechanisms of neurodegeneration, central nervous system resilience, or disability accumulation, but the evidence does not currently support individual genotyping to guide treatment decisions or patient counseling. Kreft et al. therefore emphasize the need for independent replication, standardized disability phenotyping, larger longitudinal cohorts, and careful distinction between statistical association and clinical prediction. In practical terms, MS management should continue to rely on integrated clinical assessment, MRI activity, relapse history, disability trajectory, and treatment response rather than isolated severity genotypes.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Kreft, K. L., Uzochukwu, E., Loveless, S., Willis, M., Wynford‐Thomas, R., Harding, K. E., ... & Robertson, N. P. (2024). Relevance of multiple sclerosis severity genotype in predicting disease course: a real‐world cohort. Annals of Neurology, 95(3), 459-470.
